AIM ImmunoTech (AIM) Registration filing summary

Company overview and business model

• Focuses on immuno-pharma, developing nucleic acids and natural interferon to enhance antiviral defense, with lead products Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa).

• Ampligen is being developed for late-stage pancreatic cancer, other cancers, viral diseases, and immune disorders; approved in Argentina for severe Chronic Fatigue Syndrome.

• Ongoing clinical trials for Ampligen in pancreatic cancer, ME/CFS, post-COVID fatigue, and as a vaccine adjuvant.

• Strategic focus on late-stage pancreatic cancer due to high unmet need and limited competition, leveraging orphan drug exclusivity and broad IP protection.

Financial performance and metrics

• Last reported sale price of common stock was $0.40 per share on June 17, 2026.

• 27,724,245 shares outstanding before the offering; up to 40,801,334 shares if all warrants are exercised.

• Company received $1.3 million gross proceeds from the June 2026 registered offering; potential for $5.5 million additional proceeds if all warrants are exercised for cash.

Use of proceeds and capital allocation

• Will not receive proceeds from stockholder sales; proceeds from warrant exercises (if any) will be used for general corporate purposes and working capital.

• Management has broad discretion over use of any proceeds from warrant exercises.